Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, January 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 2,501)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

patent: 5 patents
wikipedia: 6 Wikipedia pages

Citations

dimensions_citation: 225 Dimensions

Readers on

mendeley: 244 Mendeley

Summary Blogs Policy documents Patents Wikipedia Dimensions citations

So far, Altmetric has seen 5 patents that reference this research output.

Methods of treating HER2-positive metastatic breast cancer

Grant US-11406715-B2

United States of America

Personalized protease assay to measure protease activity in neoplasms

Grant US-10385380-B2

United States of America

ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF

Application EP-3480215-A1

European Patent Office

METHODS OF TREATING HER2-POSITIVE LOCALLY ADVANCED OR PREVIOUSLY UNTREATED METASTATIC…

Application WO-2016196373-A3

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 1 additional patents.